Embed Size (px)
Citation preview
KEYNOTE PRESENTATIONS INCLUDE: Dr Bernard A. Fox, Chief, Molecular & Tumour Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, USA
Professor David W.Scott, Vice Chair for Research Department of Medicine, Uniformed Services University of Health Sciences, USA
Dr Alan Korman, Vice President, Discovery Research, Bristol Myers Squibb, USA
Dr Michael Covington, CMC Senior Director, Regulatory Affairs, Dendreon, USA
Dr Michael Hanna, Founder and Chairman, Vaccinogen, USA
Dr Kalpit Vora, Director, Vaccine Basic Research, Merck, USA
EUROPE’S EVENT OF CHOICE FOR SENIOR LEVEL IMMUNOTHERAPY PROFESSIONALS:Dr Gary Starling, Director, Oncology Biologics, Abbott, USAProfessor Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono, GermanyDr John Trizzino, CEO, ImmunoVaccine, CanadaDr Harpreet Singh, Managing Director, Chief Scientific Officer, Immatics Biotechnologies GmbH, GermanyDr Reiner Laus, President and Chief Executive Officer, BN ImmunoTherapeutics, USADr Johannes Streffer, Senior Director, Neuroscience Development, Janssen – Pharmaceutical Companies of Johnson and Johnson, BelgiumDr Matthew Albert, Director, Research, INSERM, FranceProfessor Inge Marie Svane, MD, Director , Center for Cancer ImmuneTherapy- CCIT, Department of Oncology and Haematology, Herlev Hospital, Copenhagen University, DenmarkDr Gary Wood, President & CEO, TVAX Biomedical, USADr Genevieve Inchauspe, Department Head, Infectious Diseases, Transgene, FranceDr Richard Harrop, Head, Clinical Analysis, Oxford Biomedica, UKDr Michael Har-Noy, CEO/CTO, Immunovative Therapies, IsraelProfessor Viktor Umansky, German Cancer Research Center, Heidelberg and University Hospital Mannheim, GermanyDr William Grossman, Senior Vice President, Research & Development, Biothera, USADr Ronald Ellis, Senior Vice President, Research and Development, NasVax Ltd, IsraelDr Guy-Charles F. de La Horie, CEO, NeoVacs, FranceDr Khursheed Anwer, President and CSO, EGEN, Inc., USADr Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences, USADr Charles A. Nicolette, Chief Scientific Officer, Vice President, Research and Development, Argos Therapeutics, Inc., USADr Cedrik M. Britten, Vice President R&D, Ribological GmbH, Germany
Pre-Conference Workshop W: Tuesday 4th December 2012
Clinical Trial Design: The Key to SuccessLeaders: Dr John Trizzino, ImmunoVaccine, Canada Dr Gary Wood, TVAX Biomedical, USA Dr Charles A. Nicolette, Argos Therapeutics, USA Dr David Edwards, Cancer Research UK, UK Dr Thomas Felzmann, Activartis Biotech GmbH, Germany
Evening Seminar X: Wednesday 5th December 2012
Practical Advice on Successfully Filing IND ApplicationsLeader: Dr Michael Covington, Dendreon, USA
Post-Conference Workshop Y: Friday 7th December 2012
Antibodies: Targeted Therapy as an ImmunomodulatorLeaders: Dr Alan Korman, Bristol Myers Squibb, USA &
Dr Gary Starling, Abbott, USA
Maximise your time out of the office with these BRAND NEW training courses!
Find winning strategies to improve your immunotherapy development programme• Hear the latest research driving immunotherapy development
and new applications for increasing immune response: Updates and case studies from Dendreon, Bristol Myers Squibb, Merck, Vaccinogen and INSERM
• Discover which immunotherapy approaches are most effective and successful: 8 case studies covering active, passive and non-specific immunotherapy
• Generate the correct pre-clinical data to ensure successful development into the clinic: Data from Argos Therapeutics, Biothera, Janssen,Uniformed Services University and more
• Establish efficient and cost-effective clinical trials with a dedicated session on reliable patient populations and immune monitoring techniques
• Work out the best delivery method for your immunotherapy with leading industry insight on local and nanodelivery
Sponsor:
Register online: www.informa-ls.com/immunotherapiesBookings Hotline +44 (0)20 7017 7481
Fax +44 (0)20 7017 7823email: [email protected]
Please quote: CQ3486
Bringing together industry and academia to maximise the immune response, optimise clinical development and boost commercial success of immunotherapies
Wednesday 5 – Thursday 6 December 2012, Sheraton Brussels Hotel, Brussels, Belgium
Informa Life Sciences’ Inaugural
Immunotherapies & Cancer Vaccines
With 3 of the top 10 drugs predicted to be immunotherapeutics by
2014, discover how leading pharma companies
are maximising development programmes
for this lucrative
market
Media partners:
25+ Speakers – 25+ Case Studies – 10+ Hours of Networking and Partnering Opportunities
PART OF
50% discounts
for SMEs and Academics
To Register Tel: +44 (0)20 7017 7481 Fax: +44 (0)20 7017 7823 Email: [email protected] Web: www.informa-ls.com/immunotherapies Please Quote: CQ3486
DAY ONE: WEDNESDAY 5 DECEMBER 201208.00 Registration and Opening of the VIC Congress Exhibition Hall
08.55 Chairperson’s Opening
Cutting-Edge Research Driving Immunotherapy Development
09.05 THE LATEST DEVELOPMENT UPDATES ON PROVENGE Sipuleucel-T for prostate cancer: Development of the first approved active
immunotherapy Sipuleucel-T, the first FDA approved autologous cellular immunotherapy for cancer,
is designed to stimulate the immune system against prostate cancer. Challenges in the commercialisation of Sipuleucel-T in the United States and Europe will be discussed including regulatory, education, supply, reimbursement, and the changing therapeutic landscape.
Dr Michael Covington, CMC Senior Director, Regulatory Affairs, Dendreon, USA
09.35 THE LATEST UPDATES ON THE IMPROVEMENTS TO IPILIMUMAB The latest developments in improving Yervoy, and CTLA-4 and PD-1
Dr Alan Korman, Vice President, Discovery Research, Bristol Myers Squibb, USA
10.05 Potential molecular pathways to modulate for the success of immunotherapies This presentation will discuss pathways to break tolerance (adjuvants and co-stimulations to
overcome immune-anergy and molecules that block immune-inhibitory pathway). These may help focus our understanding why chronic infectious agents and tumours evade immunity.
Dr Kalpit Vora, Director, Vaccine Basic Research, Merck, USA
10.35 Morning Coffee and Poster/Exhibition Viewing Time 11.05 KEYNOTE PRESENTATION The impact of genomic sequencing data in cancer immunotherapy At the cellular level it is clear that cancer is a genetic disease arising as a clone that expands
and grows in an unregulated manner. While it has always been presumed that neoplasia is a consequence of somatic cell mutations, only in the last few years has the magnitude and diversity of these mutations been elucidated by modern DNA sequencing technology. Immunotherapy is the premier biological approach to targeted therapy. This presentation will discuss the consequences of this new knowledge of tumour cell biology to the immunotherapeutic approach to treating cancer.
Dr Michael Hanna, Founder and Chairman, Vaccinogen, USA
11.35 Bladder cancer: Lessons from 35 years of a clinical immunotherapy To find out more information about this presentation, please visit the conference website at
www.informa-ls.com/immunotherapies Dr Matthew Albert, Director, Research, INSERM, France
Novel Approaches for Maximising Immune Response
12.05 Biomarker-guided development of cancer vaccines and combination therapies Immunotherapy development is complex requiring rational selection and combination of
the right antigens, immunomodulators, standard of care and patient population. In this presentation – using two novel peptide-based cancer immunotherapy candidates for treatment of renal cell cancer (IMA901) and colorectal cancer (IMA910) as examples – the use of novel pharmacodynamic and prognostic/predictive biomarkers to rationally guide clinical development of immunotherapy combinations will be discussed.
Dr Harpreet Singh, Managing Director, Chief Scientific Officer, Immatics Biotechnologies GmbH, Germany
SPOTLIGHT PRESENTATION These sessions are hosted by leading companies operating in the field of immunotherapies and
cancer vaccines, and offer an opportunity to learn about the latest developments in the industry. If you would like to host a spotlight presentation, please contact [email protected] or +44 (0) 207 017 4447
12.35 Lunch and partnering time
13.35 Immunostimulatory therapies: Immunocytokines/Cancer vaccines To find out more information about this presentation, please visit the conference website at
www.informa-ls.com/immunotherapies Professor Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck
Serono, Germany
14.05 Novel monoclonal antibody therapeutic for Alzheimer’s disease Amyloid precursor protein (APP) is a primary molecule in AD pathogenesis. We employ a MAb (BBS)
that binds to the BACE cleavage site on cell-surface APP. Transgenic AD mice treated with BBS MAb compared to control MAb showed significant reductions in intra- and extra-cellular Aß, significantly improved performance in behavioural tests to the same level as that of non-transgenic mice, and reduced levels of astrocytosis indicating improved safety. The rapid cellular internalisation of the MAb after binding to APP may be beneficial for avoiding microglia and complement activation that have been reported for anti-Aß Abs that bind to amyloid plaques. The BBS MAb is a strong candidate for clinical development.
Dr Ronald Ellis, Senior Vice President, Research and Development, NasVax Ltd, Israel
14.35 Immunologic mechanisms driving the combinatorial activity of elotuzumab and lenalidomide in multiple myeloma models
Elotuzumab, a humanised monoclonal antibody, has shown promise as a combination partner of lenalidomide/dexamethasone for the treatment of relapsed or refractory Multiple Myeloma. Randomised Phase 3 clinical studies are underway to examine the effect of elotuzumab in combination with len/dex on progression-free survival in newly diagnosed and relapsed/refractory MM patients. The immunologic mechanisms underlying the combinatorial activity have been dissected in xenograft models in vivo and in vitro using a co-culture model consisting of peripheral blood lymphocytes and Myeloma cell lines.
Dr Gary Starling, Director, Oncology Biologics, Abbott Biotherapeutics, USA
15.05 Perspectives on T cell therapy for treatment of melanoma; a succesfull combination of chemotherapy and immunotherapy
T-cell therapy is a very promising new strategy for treatment of metastatic melanoma and a fascinating example of successful combination of intensive chemotherapy and immunotherapy. Tumour infiltrating lymphocytes (TILs) can be isolated from surgical removed tumour lesion and extensively expanded in vitro. TIL-based therapy is given in three phases; conditioning high-dose chemotherapy, TIL infusion, and high dose IL-2. Impressive objective responses are seen probably with curative potential. New perspectives on this therapy will be discussed.
Professor Inge Marie Svane, MD, Director , Center for Cancer ImmuneTherapy- CCIT, Department of Oncology and Haematology, Herlev Hospital, Copenhagen University, Denmark
15.35 Afternoon Tea, and Poster/Exhibition Viewing Time
16.05 A novel approach to cancer immunotherapy combining cancer cell vaccination and killer T cells
Research suggests that an efficacious immunotherapeutic strategy should involve significant T cell mediated cancer cell killing. We have developed a cancer immunotherapy platform that combines cancer cell vaccination and intravenous infusion of ex vivo-activated killer T cells to produce significant T cell-mediated cancer cell killing. We will discuss results of our research demonstrating the therapeutic benefits that can be achieved with this strategy.
Dr Gary Wood, President & CEO, TVAX Biomedical, USA
16.35 Harnessing the power of the graft vs. tumour effect of non-myeloablative allogeneic stem cell transplants to enhance the effectiveness of cancer vaccine strategies
The immune mechanism of non-myeloablative allogeneic stem cell transplants, called the graft vs. tumour (GVT) effect, has been shown capable of debulking chemotherapy-resistant disease in both haematological and metastatic solid tumour settings. However, the use of this powerful mechanism has been limited by the severe and often lethal side-effect, called graft vs. host disease (GVHD), that is intimately coupled to, and necessary for, the GVT mechanism. A novel bioengineered allograft, called AlloStimTM, has been developed that is designed to elicit an autologous GVT effect without GVHD toxicity. The use of the “danger signals” of AlloStimTM to provide enhanced adjuvant effects to increase the effectiveness of cancer vaccines is discussed.
Dr Michael Har-Noy, CEO/CTO, Immunovative Therapies, Israel
17.05 Therapeutic vaccination to fight cancers and chronic infectious diseases: Phase II clinical trials using poxvirus MVA-based vaccines
It is becoming increasing clear that a number of immune mechanisms underlying the development of cancers and those associated with establishment of chronic infections are shared (e.g. presence and role of regulatory T-cells, T-cell inhibitory signals, epitope escape or epitope hiding). Therapeutic vaccines aiming at restoring and/or enhancing host’s effective immune responses are being actively developed in both fields and their use is moving into combination with standards-of-care. It is logical to believe that a given vaccine platform with its intrinsic specificities, if resulting in increased efficacy in one field (cancer) may hold promises in the other (chronic viral infection). We will discuss results from two phase II clinical trials that have tested the performance of MVA-derived vaccines in the treatment of metastatic Non Small Cell Lung Cancer (NSCLC) and Chronic Hepatitis C viral infection.
Dr Genevieve Inchauspe, Department Head, Infectious Diseases, Transgene, France
17.35 Proof of concept of therapeutic vaccine in the treatment of auto-immune disease: Anti-TNF in Crohn’s disease and anti-IFN in lupus
To find out more information about this presentation, please visit the conference website at www.informa-ls.com/immunotherapies
Dr Guy-Charles F. de La Horie, CEO, NeoVacs, France
18.05 Closing Remarks from the Chairperson and End of Day One
‘Immunotherapies & Cancer Vaccines 2012 provides a great opportunity to learn about the latest developments in the immunotherapy world from the people who are actually making it happen. Because it combines quality input and networking, this conference is not to be missed’ Dr Michael Hanna, Founder and Chairman, Vaccinogen, USA
PRE-CONFERENCE WORKSHOP: TUESDAY 4TH DECEMBER 2012 W
Clinical Trial Design: The Key to SuccessRegistration 08.30 – Start 09.00 – End 15.30 – Workshop material, refreshments and lunch will be provided
The recent success of therapies such as Ipilimumab and Sipuleucel have drawn investigators’ attention to the power of immunotherapy in the treatment of cancer. However, translating an idea to the clinic is fraught with difficulty. The purpose of this workshop will be to highlight some
of these challenges. • What constitutes cancer immunotherapy? • Translating immunotherapies• What should the preclinical package look like?
• How do we translate the idea into the clinic? • What constitutes success in the clinic?• How do we measure tumour response?• What is the most appropriate patient population?
Workshop leaders: Dr John Trizzino, CEO, ImmunoVaccine, Canada Dr David Edwards, Non-Clinical Safety Manager, Cancer Research UK, UK Dr Gary Wood, President & CEO, TVAX Biomedical, USA Dr Charles A. Nicolette, Chief Scientific Officer, Vice President, Research and Development, Argos Therapeutics, Inc., USA Dr Thomas Felzmann, CEO, Activartis Biotech GmbH, Germany
Feedback on the 2012 programme:
EVENING SEMINAR: WEDNESDAY 5TH DECEMBER 2012 X
Practical Advice on Successfully Filing IND ApplicationsRegistration 18.15 – Start 18.30 – Networking, Dinner and refreshments will be provided
Workshop leader: Dr Michael Covington, CMC Senior Director, Regulatory Affairs, Dendreon, USA
This interactive seminar provides the essential platform for industry professionals to understand how to best
overcome the major regulatory hurdles when submitting an IND proposal. This seminar will discuss:
What will be discussed?• Considerations for various disease targets• Key regulatory requirements- practical insight• Insight into preclinical data required
To Register Tel: +44 (0)20 7017 7481 Fax: +44 (0)20 7017 7823 Email: [email protected] Web: www.informa-ls.com/immunotherapies Please Quote: CQ3486
Essential regulatory insight
to achieve successful IND
applications
4 real-life case studies on designing the most effective
& successful immunotherapy
clinical trials
Upda
tes on
curre
ntly m
arke
ted
immu
nothe
rapie
s
Product at late
stage clinical phase
Free with a 4 day pass
To Register Tel: +44 (0)20 7017 7481 Fax: +44 (0)20 7017 7823 Email: [email protected] Web: www.informa-ls.com/immunotherapies Please Quote: CQ3486
DAY TWO: THURSDAY 6 DECEMBER 201208.50 Chairperson’s Opening Remarks
Pre-Clinical Trial Assessment and Immune Modulation
KEYNOTE PRESENTATION09.00 Applications and understanding of Immunoscore Pre-existing antitumor immune responses (Immunoscore) predict better outcomes in patients with
a range of malignancies. Clinical trials must consider these parameters and stratify accordingly. It appears that current therapies fail in immunoscore negative patients. Understanding the mechanisms responsible for low immunoscore and identification of novel “non-tolerant” tumour targets may provide opportunities to induce immunity and improve outcomes.
Dr Bernard A. Fox, Chief, Molecular & Tumour Immunology, Robert W. Franz Cancer Research Centre, Earle A. Chiles Research Institute, Providence Cancer Centre, USA
09.30 Immunomodulatory strategies: approaches to reduce immunogenicity The immunogenicity of therapeutic proteins can have profound effects on their efficacy and could
cause adverse reactions. Understanding how to prevent or reverse this immunogenicity will be the focus of this presentation. Tolerance induction using IgG and Fc conjugated fusion proteins has been studied for over three decades. The basis of this tolerogenicity will be discussed, as well as deimmunisation approaches to immuno-modulation.
Professor David W. Scott, Vice Chair for Research Department of Medicine, Uniformed Services University of Health Sciences, USA
10.00 Case study: key updates on Janssen’s bapineuzumab programme This presentation will discuss the latest information of the bapineuzumab programme as well
as broader discussions on immunotherapy in neurodegeneration with the example of Abeta immunotherapies.
Dr Johannes Streffer, Senior Director, Neuroscience Development, Janssen – Pharmaceutical Companies of Johnson and Johnson, Belgium
10.30 Immune responses induced by AGS-003 predict clinical outcomes with statistically significant accuracy in metastatic renal cancer patients
We believe that the strategy behind immunotherapies designed to induce immunity against non-mutated self-antigens is fundamentally flawed since high avidity T cells reactive to them were eliminated during the process of negative selection, the central tolerance mechanism that protects against autoimmunity. This may be one reason why correlations between immunity to normal antigens and clinical outcomes have been elusive. In a phase 2 clinical study combining AGS-003, an immunotherapy targeting the entire autologous tumor antigen repertoire, with Sunitinib in newly diagnosed metastatic RCC patients we demonstrated a statistically significant correlation between the induction of anti-tumor memory T cells after 5 doses (15 weeks) and survival (r=.8, p<0.001) and an inverse correlation with tumor burden (r=-.6, p<0.019).
Dr Charles A. Nicolette, Chief Scientific Officer, Vice President, Research and Development, Argos Therapeutics, Inc., USA
11.00 Morning Coffee and Poster/Exhibition Viewing Time
11.30 Human immune system heterogeneity: impact on translating preclinical models to the clinic for immunotherapies
To find out more information about this presentation, please visit the conference website at www.informa-ls.com/immunotherapies
Dr William Grossman, Senior Vice President, Research & Development, Biothera, USA
12.00 Immunomodulators: Comparing the performance of different known immunomodulators
INTE
RAC
TIV
ED
ISC
USS
ION
PA
NEL • Overcoming the lack of systematically generated data, especially in humans
• How to best design an effective immunotherapy regimen Contributions from: Dr Charles A. Nicolette, Chief Scientific Officer, Vice President, Research and Development,
Argos Therapeutics, Inc., USA Plus other speakers of the day
12.30 Preclinical development of cancer vaccines: obstacle and hurdles This presentation will discuss the challenges and opportunities of efficacy models, as well as to
what extent safety needs to be monitored. Dr Emmanuelle Cornali, Head, Business Development, Aurigon Life Sciences, Germany
13.00 Lunch and partnering time
Designing Appropriate and Successful Clinical Trials
14.00 The changing regulatory landscape for immunotherapies & cancer vaccines The recent approvals of a vaccine to treat prostate cancer and an immune-modulatory antibody for
malignant melanoma have laid the foundation for the clinical subspecialty of immuno-oncology.
We have seen how R&D efforts had a dramatic impact on new regulation and can expect that the forming regulatory landscape will also influence the clinical development paths for future immune therapeutics. The lecture will give an overview on the changing regulatory landscape and its implications for development of new cancer immunotherapies.
Dr Cedrik M. Britten, Vice President R&D, Ribological GmbH, Germany
14.30 Cancer immunotherapy with recombinant poxviral vaccines BN ImmunoTherapeutics is developing poxvirus-based immunotherapies for the treatment
of cancer. The company’s lead program is PROSTVAC®, a therapeutic vaccine candidate for treatment of advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. Other product candidates in clinical development, which are based on the same platform technology, target breast, lung, ovarian and other cancers.
Dr Reiner Laus, President and Chief Executive Officer, BN ImmunoTherapeutics, USA
15.00 Immunotherapeutic strategies overcoming immunosuppression in the tumour microenvironment
Insufficient anti-tumour reactivity is due to the chronic inflammation represented by infiltrating leukocytes and soluble mediators leading to cancer progression. Using ret transgenic mouse melanoma model that mimics human melanoma, we demonstrated increased levels of chronic inflammatory factors and immunosuppressive cells in melanoma lesions correlated with tumor progression. Inhibitors of immunosuppressive tumour microenvironment induced anti-tumour effects and should be applied together with other melanoma immunotherapies.
Professor Viktor Umansky, German Cancer Research Center, Heidelberg and University Hospital Mannheim, Germany
15.30 Afternoon Tea and Poster/Exhibition Viewing Time
16.00 Identification of biomarkers predictive of clinical and immunological efficacy in cancer patients treated with TroVax (MVA-5T4)
Few immunotherapy compounds have demonstrated a clear link between the predicted mode of action of the product and clinical benefit. We have demonstrated that a 5T4-specific antibody response, induced by vaccination with TroVax, correlates with enhanced patient survival. Furthermore, we have identified a simple pre-treatment blood biomarker which predicts both immunological and clinical efficacy.
Dr Richard Harrop, Head, Clinical Analysis, Oxford Biomedica, UK
Delivery Systems for Administering Immunotherapies
16.30 A local immunotherapy approach for the treatment of peritoneal metastases of gynecological and gastrointestinal cancers
This presentation describes the clinical development of EGEN-001, a novel immunotherapeutic for local treatment of cancers that are metastasised to the peritoneal cavity. EGEN-001 is composed of an IL-12 plasmid and a novel lipopolymer delivery system and is designed to produce sustained local increases in IL-12 concentrations to stimulate the immune system against metastases without causing systemic toxicity.
Dr Khursheed Anwer, President and CSO, EGEN, Inc., USA
17.0 0 Rational design of targeted Synthetic Vaccine Particles (tSVP) for cancer Selecta Biosciences is a clinical stage company developing targeted Synthetic Vaccine Particles
(tSVP). A modular and self-assembling manufacturing process allows rapid optimisation of adjuvant/antigen combinations. The tSVP technology enables the use of potent adjuvants and efficient cross-presentation of antigen to cytolytic T cells. We have demonstrated potent in vivo CTL activity and therapeutic efficacy in animal models of cancer.
Dr Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences, USA
17.30 Closing Remarks from the Chairperson and End of Conference
‘Immunotherapies & Cancer Vaccines 2012 provides a great opportunity to learn about the latest developments in the immunotherapy world from the people who are actually making it happen. Because it combines quality input and networking, this conference is not to be missed’ Dr Michael Hanna, Founder and Chairman, Vaccinogen, USA
To Register Tel: +44 (0)20 7017 7481 Fax: +44 (0)20 7017 7823 Email: [email protected] Web: www.informa-ls.com/immunotherapies Please Quote: CQ3486
POST-CONFERENCE WORKSHOP: FRIDAY 7TH DECEMBER 2012 Y
Antibodies: Targeted Therapy as an ImmunomodulatorRegistration 08.30 – Start 09.00 – End 15.30 – Workshop material, refreshments and lunch will be provided
There are a variety of different immunotherapy approaches that are being explored by industry and academia at present, however with antibodies being the most successful immunomodulator targeted therapy to date, this approach is what many companies are looking into closely. This interactive and case study led workshop explores current antibody immunotherapy products on the market, how they work, what led to their success and how this approach compares to other immunotherapy products.
Topics to be discussed:• Potential antibodies • How to determine one modality from another• Clinical settings applicable for antibody use • Comparisons to cytokine • Determining the best combination of antibodies
Workshop leaders: Dr Gary Starling, Director, Oncology Biologics, Abbott Biotherapeutics, USA & Dr Alan Korman, Vice President, Discovery Research, Bristol Myers Squibb, USA
SPONSORSHIP AND EXHIBITION OPPORTUNITIES AT THE VIC CONGRESS 2012
Informa’s Immunotherapies & Cancer Vaccines conference brings together key-decision makers from across regulatory, technical, research and strategic departments and is the ideal platform for showcasing your latest technologies and services.Reasons why you should choose this event:• 4 audiences for the price of 1: 1) Immunotherapies & Cancer Vaccines, 2) Vaccine Manufacturing, 3) Veterinary Vaccines and 4) Cell Therapy Manufacturing• Partner with 200+ senior level scientists at the VIC Congress with the authority to purchase new instruments, services and products.For further information on sponsorship & exhibitions opportunities, please contact: Ben Edwards: Tel: +44 (0) 20 7017 4447 Email: [email protected]
Leading experts from BMS and Abbott present on the success
of antibody immunotherapies
Product at late
stage clinical phase
Product at late
stage clinical phase
Immunotherapies & Cancer VaccinesWednesday 5 – Thursday 6 December 2012 Sheraton Brussels Hotel, Brussels, Belgium
www.informa-ls.com/immunotherapies
5 Easy ways to Register
LS/S
B/SN
/BE/
CC/T
R
+44(0) 20 7017 7481
+44(0) 20 7017 7823
The Bookings Department Informa UK Ltd P O Box 406 Byfleet KT14 6WL
Your VIP number is on the address label. If there is no label, please quote
Terms and ConditionsFEE: This includes all technical sessions, lunch and documentation.
CANCELLATIONS: Cancellations received in writing before and on Tuesday 20 November 2012 will be subject to a service charge of £99. The full conference fees remain payable after Tuesday 20 November 2012. Substitutions are welcome at any time. It may be necessary for reasons beyond the control of the organiser to alter the content and timing of the programme or the identity of the speakers. In the unfortunate event that an event is cancelled Informa are not liable for any costs incurred by delegates in connection with their attendance. This contract is subject to English Law.
ARE YOU REGISTERED?: You will always receive an acknowledgement of your booking. If you do not receive anything, please call us on +44(0) 20 7017 7481 to make sure we have received your booking.
Yes I agree to the terms and conditions as stated on this form.
DATA PROTECTION: The personal information shown on this form, and/or provided by you, will be held on a database and may be shared with other companies in the Informa Group in the UK and internationally. If you do not wish your details to be avaialble to companies in the Informa Group please contact the Database Manager at the above address, Tel : +44 (0)20 7017 7077, Fax: +44 (0)20 7017 7828 or email: [email protected]. Occasionaly your details may be obtained from, or made avaialble to, external companies who wish to communicate with you offers related to your business activities. If you do not wish to receive these offers, please tick the box
INCORRECT MAILING If you are receiving multiple mailings or you would like us to change any details or remove your name from our database, please contact the Database Manager at the above addresss, Tel : +44 (0)20 7017 7077, Fax: +44 (0)20 7017 7828 or email: [email protected] - quoting the reference number printed on the mailing label.
ANY SPECIAL REQUIREMENTS: Please inform us if you have any special requirements by calling Customer Services on +44(0) 20 7017 7481.
Conference Documentation: Cannot Attend? For those busy executives who cannot take full advantage of this event, the papers give you a useful record of the presentations made at the event. The set of speakers papers and/or slides from the conference is available after the event for £399 + 20% VAT. Contact Customer Services on tel: +44 (0) 20 7017 7481, fax: +44 (0) 20 7017 7823 or email: [email protected]
Are we mailing you correctly? To update your contact details on our database please email [email protected]
www.informa-ls.com/immunotherapies
Head of Department:E-mail
Tel FaxBooking Contact:E-mail
Tel FaxName of CompanyDepartment
Address
City Postcode
Country
Tel Fax
Nature of Company Business
No. of employees on your site:
1) 0-49 2) 50-249 3) 250-499 4) 500-999 5) 1000+
(Mr/Mrs/Ms/Miss/Dr) Family NameE-mail
Tel Fax
ForenameJob TitleAny special requirements?
To assist us with future correspondence, please supply the following details:
DELEGATE DETAILS – Please photocopy form for multiple bookings!
Conference CQ3486CPre-Conference Workshop CQ3486WPost-Conference Workshop CQ3486YEvening Seminar CQ3486X
Follow us @VICCongress, #Immunotherapies
Step 1. Select your workshops
The VAT rate is subject to change and may differ from the advertised rate.The amount you are charged will be determined when your invoice is raised.
Step 2. Select your pass
q Pre-conference Workshop W: Clinical Trial Design: The Key to Success q Post-conference Workshop Y: Antibodies: Targeted Therapy as an Immunomodulator
q Evening Seminar X: Practical Advice on Successfully Filing IND Applications
Scan withsmartphone
QR Reader App:
Venue Details:
Sheraton Brussels Hotel Place Rogier 3, Brussels, 1210 · Belgium Phone: +32 2 2243111 Fax: +32 2 2243456 Web: www.sheratonbrussels.com
Reduced rate accommodation: the cost of accommodation is not included in the conference fee. In order to book reduced rate accommodation please visit the section “Accommodation” on the event website www.informa-ls.com/immunotherapies. Please book early to avoid disappointed (discounted rates at the Sheraton Brussels Hotel are available only until 3rd November 2012 and are subject to availability)
Pass Code Book Before
Friday 14th September 2012 Save
Book Between Friday 14th September and Friday 2nd November 2012
Save Book After
Friday 2nd November 2012Save
Academic /SME - 50% off full industry prices
2 Day Pass: Conference Only CQ3486C £1499 + VAT @ 21% = £1813.79 □ £200 £1599 + VAT @ 21% = £1934.79 □ £100 £1699 + VAT @ 21% = £2055.79 □ -£849.5 + VAT @ 21% =
£1027.89
2 Day Pass: Conference + Evening Seminar
CQ3486CX £1998 + VAT @ 21% =£2417.58 □ £200 £2098 + VAT @ 21% = £2538.58 □ £100 £2198 + VAT @ 21% = £2659.58 □ -£1099 + VAT @ 21% =
£1329.79
3 Day Pass: Conference + Pre or Post Conf Workshop
CQ3486CW/Y £2199+ VAT @ 21% = £2660.79 □ £200 £2299 + VAT @ 21% = £2781.79 □ £100 £2399 + VAT @ 21% = £2902.79 □ -£1199.5 + VAT @ 21% =
£1451.39
3 Day Pass: Conference + Pre or Post Conf Workshop + Evening Seminar
CQ3486CW/YX £2598 + VAT @ 21% = £3143.58 □ £300 £2698 + VAT @ 21% = £3264.58 □ £200 £2798 + VAT @ 21%= £3385.58 □ £100£1399 + VAT @ 21% =
£1692.79
FULL Pass: Conference + Pre & Post Conf Workshop + FREE Evening Seminar
CQ3486CWYX £2899 + VAT @ 21% = £3507.79 □ £700 £2999 + VAT @ 21% = £3628.79 □ £600 £3099 + VAT @ 21% =£3749.79 □ £500£1699 + VAT @ 21% =
£2055.79
Group Bookings: To take advantage of group bookings please contact Simon Lau, Tel: +44(0) 20 7017 7165e-mail: [email protected]
